🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new drug called Avlayah to treat Hunter syndrome, a rare genetic disease that affects the brain and nervous system. Hunter syndrome happens when the body can't break down certain substances properly, causing serious health problems over time. This approval means patients with Hunter syndrome now have a new treatment option available to help manage the neurologic symptoms of their condition.
WHY IT MATTERSThis is the first FDA approval of Avlayah specifically for the neurologic manifestations of Hunter syndrome, offering patients a new therapeutic option for managing brain and nervous system symptoms that were previously difficult to treat.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.
WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
ResearchPUBMEDMar 26
Doctors have identified a rare form of brain inflammation called unilateral primary angiitis of the central nervous system (U-PACNS) that affects only one side of the brain instead of both sides. This condition is often missed or confused with other diseases like brain tumors or multiple sclerosis because it looks similar on imaging tests. The article explains how doctors can better recognize and diagnose this condition by understanding its unique features.
WHY IT MATTERSIf you've been diagnosed with a one-sided brain lesion or inflammation that doctors can't fully explain, this research helps clarify that U-PACNS should be considered in your differential diagnosis, potentially changing your treatment approach.
ResearchCLINICALTRIALSMar 26
Researchers at a hospital in France are collecting biological samples (like blood) from 1,000 patients with rare nervous system diseases that may be caused by the immune system attacking the body. These samples will help scientists find new ways to diagnose and treat these diseases by identifying special markers in the blood that show disease activity.
WHY IT MATTERSIf you have a rare autoimmune neurological disease, participating in this sample collection could help researchers discover new biomarkers and treatments specifically for conditions like yours.
Clinical trialCLINICALTRIALSMar 26
Researchers at Vanderbilt University are studying how the nervous system controls blood vessels in the abdomen and how this might cause high blood pressure in people with certain rare nervous system disorders. The study focuses on three conditions where the nervous system doesn't work properly: Multiple System Atrophy, Orthostatic Hypotension, and Supine Hypertension. By understanding this connection, doctors may find new ways to treat high blood pressure in these patients.
WHY IT MATTERSThis trial directly addresses a poorly understood cause of high blood pressure in patients with Multiple System Atrophy and related autonomic nervous system disorders, potentially leading to better treatment options for this hard-to-manage symptom.